sofosbuvir/velpatasvir
Sign in to saveAlso known as sofosbuvir / velpatasvir, Epclusa, Sofosvel, Velasof, Velpanat
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six. It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS. It is taken by mouth.
Medication
- Brand names
- Epclusa
- Drug class
- Antivirals for treatment of HCV infections
- Active ingredients
- sofosbuvir, velpatasvir, sofosbuvir / velpatasvir
- Dosage form
- Oral Tablet, Oral Pellet
Clinical Trials
61 registered- PHASE3ACTIVE_NOT_RECRUITINGC-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVAtea Pharmaceuticals, Inc. · NCT06868264
- PHASE4COMPLETEDA Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction ClinicCommunity Research Initiative of New England · NCT03235154
- PHASE3COMPLETEDEfficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionGilead Sciences · NCT02480712
- PHASE3COMPLETEDSafety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral TherapyGilead Sciences · NCT02607800
- PHASE2COMPLETEDViral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT02468648
- COMPLETEDA Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseGilead Sciences · NCT01457768
Wikidata facts
- Instance of
- essential medicine
- Has part
- velpatasvir
Show 2 more facts
- medical condition treated
- hepatitis C
- has active ingredient
- sofosbuvir
Sources (2)
via Wikidata · CC0
~6 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacokinetics
- History
- References
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six. It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS. It is taken by mouth.
In March 2020, sofosbuvir/velpatasvir was approved for use in the United States to treat hepatitis C virus (HCV) in children ages six years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes—or strains—without cirrhosis (liver disease) or with mild cirrhosis. Sofosbuvir/velpatasvir in combination with ribavirin is indicated for the treatment of children six years and older or weighing at least 37 pounds with severe cirrhosis.
Excerpted from Wikipedia’s “sofosbuvir/velpatasvir” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0